Health Care Supplies

Embecta

Embecta released FY2026 Q2 earnings on May 5 Pre-Market (EST), actual revenue USD 221.8 M (forecast USD 235.66 M), actual EPS USD -0.07 (forecast USD 0.3033)

Embecta released FY2026 Semi-Annual earnings on May 5 Pre-Market EST, with actual revenue of USD 483 M and EPS of USD 0.67

Embecta to Release FY2026 Q2 Earnings on May 5, Pre-Market EST; Forecast Revenue USD 235.67 M, EPS USD 0.3033

Embecta released FY2026 Q1 earnings on February 5 Pre-Market EST, actual revenue USD 261.2 M (forecast USD 258.07 M), actual EPS USD 0.74 (forecast USD 0.58)

Embecta to Release FY2026 Q1 Earnings on February 5, Pre-Market EST; Forecast Revenue USD 258.07 M, EPS USD 0.58

Embecta Corporation to Speak at JPMorgan Healthcare Conference

Embecta released FY2025 Q4 earnings during market hours on November 25 (EST), with actual revenue of USD 264 M (forecast USD 265.66 M) and actual EPS of USD 0.4442 (forecast USD 0.4166)

Embecta released FY2025 Annual Earnings on November 25 During-Market EST, actual revenue USD 1.08 B (forecast USD 1.082 B), actual EPS USD 1.62 (forecast USD 1.5966)

Embecta to Release FY2025 Q4 Earnings on November 25 During Market Hours (EST), Forecast Revenue USD 265.66 M, EPS USD 0.4166

Embecta released FY2025 9 Months Earnings on August 8 Pre-Market (EST), with actual revenue of USD 816.4 M and actual EPS of USD 1.1779

Embecta released FY2025 Q3 earnings on August 8 Pre-Market (EST), actual revenue USD 295.5 M (forecast USD 278.15 M), actual EPS USD 0.7779 (forecast USD 0.64)

Embecta to Release FY2025 Q3 Earnings on August 8, Pre-Market EST; Forecast Revenue USD 278.15 M, EPS USD 0.64

Embecta Corp. Cuts 2025 Fiscal Year Revenue Guidance

Embecta Corp. Expands into Broader Medical Products and Attends Investor Meetings

Mizuho Downgrades Embecta Price Target to $13.00

Director David F. Melcher Acquires Embecta Corporation Common Stock

Mizuho Downgrades EMBECTA Target Price to $13

Embecta Corp. to Host First Analyst and Investor Day on NASDAQ

Embecta's Quarterly Earnings Per Share Exceed Expectations

Embecta released FY2025 Q2 earnings on May 9 After-Market EST, actual revenue USD 259 M (forecast USD 261.77 M), actual EPS USD 0.4 (forecast USD 0.16)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Ordinary dividend (cash)

Ex Date: 2026.05.28 (EST), Cash dividend 0.01 USD

EMBC

Embecta's CEO Devdatt Kurdikar announced a U.S. business reset due to share loss, market softness, and inventory issues, impacting fiscal 2026 guidance. The company is diversifying beyond insulin injections, developing new products, and exploring opportunities in GLP-1 drugs. Kurdikar highlighted the importance of a recent Owen Mumford deal to expand their medical device platform. Despite challenges, there are signs of stabilization in share loss and ongoing assessments of market conditions.

Market Beat

iShares US Medical Devices

SPDR S&P Health Equip

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification

Embecta Corp. has completed its acquisition of Owen Mumford Holdings Limited for £100 million, with potential additional payments based on sales of the Aidaptus® auto-injector. This acquisition enhances Embecta's transformation into a comprehensive medical supplies company, expanding its drug delivery capabilities and operational efficiencies in chronic care markets.

Fidelity

embecta Completes Acquisition of Owen Mumford Holdings Limited

Embecta (EMBC) reported Q1 2026 revenue of $261.2 million and EPS of $0.75, with a trailing twelve-month revenue of $1.1 billion and EPS of $2.38. The company achieved a net profit margin of 12.9%, up from 5.3% the previous year, despite flat revenue growth of 0.8%. While bullish investors highlight the margin improvement, bears caution that sustaining this margin may be challenging due to potential one-off benefits and negative shareholders' equity. Embecta's stock trades at a P/E of 1.7x, significantly below its DCF fair value of $24.48, indicating a potential investment opportunity amid risks.

Simplywall

Embecta (EMBC) Margin Expansion To 12.9% Tests Bearish Earnings Sustainability Narrative

Embecta's stock plummeted 57.8% following a disappointing fiscal Q2 report, with adjusted earnings per share of $0.27 on sales of $221.8 million, missing analyst expectations of $0.42 per share and $235.7 million in sales. The company also reported a 14.4% year-over-year sales decline and lowered its full-year sales guidance to $1.015-$1.035 billion, raising concerns about its growth outlook. Additionally, adjusted operating margins are now expected to be between 22.25% and 23.25%, down from previous estimates of 29%-30%.

nasdaq

Nasdaq

NVIDIA

Intel

NVIDIA Corporation

Why Embecta Stock Plummeted Today

Embecta Corp. (NASDAQ:EMBC) reached a new 52-week low of $3.89 after reporting weaker-than-expected earnings of $0.27 per share, missing estimates by $0.15. Revenue fell 14.4% year-over-year to $221.80 million, below the $235.67 million forecast. The company also announced a quarterly dividend of $0.01, with a yield of 1.0%. Analysts have mixed ratings, with a consensus "Hold" rating and a target price of $18.50. Embecta's stock has declined 57.8% and is primarily owned by institutional investors, holding 93.83% of shares.

Mizuho Financial

Mizuho Financial Group, Inc.

ROYAL BANK OF CANADA

UBS Group AG

Becton Dickinson and

Embecta (NASDAQ:EMBC) Reaches New 12-Month Low After Earnings Miss

Embecta Corp. reported Q3 2026 results with revenue of $221.8M, down 14.4% YoY, and a net loss of $4.1M, resulting in a diluted EPS of $(0.07). This contrasts with the previous year's revenue of $259M and net income of $23.5M. The decline was attributed to volume decreases and pricing pressures. The company is facing challenges from commoditization and competitive pricing, while also managing raw material supply disruptions. Operational actions include acquiring Owen Mumford and launching a $100M share repurchase program.

TradingView

Embecta Corp. 3Q 2026: Revenue $221.8M, EPS $(0.07) — 10-Q Summary

FTRE

VRDN

CLRB

BDSX

In Tuesday's intraday session, several health care stocks experienced significant movements. Viridian Therapeutics (VRDN) surged 30.7% to $18.37, while Biodesix (BDSX) rose 29.37% to $14.58. Other gainers included Biodexa Pharmaceuticals (BDRX) up 27.24%, Fortrea Holdings (FTRE) up 25.14%, and Cellectar Biosciences (CLRB) up 24.13%. Conversely, Embecta (EMBC) plummeted 55.2% to $4.14, GeneDx Holdings (WGS) fell 49.81% to $34.09, and Picard Medical (PMI) decreased 41.2% to $0.21. Overall, the session highlighted notable volatility in health care stocks.

Embecta(EMBC.US)